Haematological and nutritional prognostic biomarkers for patients receiving CROSS or FLOT

被引:3
作者
McNamee, Nicholas [1 ,5 ]
Nindra, Udit [2 ]
Shahnam, Adel [1 ]
Yoon, Robert [2 ]
Asghari, Ray [3 ]
Ng, Weng [2 ]
Karikios, Deme [4 ]
Wong, Mark [1 ]
机构
[1] Westmead Hosp, Dept Med Oncol, Sydney, Australia
[2] Liverpool Hosp, Dept Med Oncol, Sydney, Australia
[3] Bankstown Lidcombe Hosp, Dept Med Oncol, Sydney, Australia
[4] Nepean Hosp, Dept Med Oncol, Sydney, Australia
[5] Westmead Hosp, Crown Princess Mary Canc Ctr, 166-174 Hawkesbury Rd, Sydney, NSW 2145, Australia
关键词
Carboplatin and paclitaxel concurrent chemoradiotherapy (CROSS); fluorouracil (FLOT); neutrophil-lymphocyte ratio (NLR); platelet-lymphocyte ratio (PLR); prognostic marker; oesophageal; gastro-oesophageal; ESOPHAGEAL; CANCER; PREDICT; CHEMORADIOTHERAPY; METASTASIS; MANAGEMENT; JUNCTION; OUTCOMES; MARKERS; CELLS;
D O I
10.21037/jgo-22-886
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Neoadjuvant carboplatin and paclitaxel with radiotherapy (CROSS) and perioperative docetaxel, oxaliplatin, calcium folinate and fluorouracil (FLOT) are widely used for gastric (GC), gastrooesophageal junction (GOJ) and oesophageal cancers (OC). Prognostic and predictive markers for response and survival outcomes are lacking. This study evaluates dynamic neutrophil-lymphocyte ratios (NLR), plateletlymphocyte ratios (PLR), albumin and body mass index (BMI) as predictors of survival, response and toxicity. Methods: This multi-centre retrospective observational study across 5 Sydney hospitals included patients receiving CROSS or FLOT from 2015 to 2021. Haematological results and BMI were recorded at baseline and pre-operatively, and after adjuvant treatment for FLOT. Toxicities were also recorded. An NLR >_2 and PLR >_200 was used to stratify patients. Univariate and multivariate analyses were performed to determine predictors of overall survival (OS), disease free survival (DFS), rates of pathological complete response (pCR) and toxicity. Results: One hundred sixty-eight patients were included (95 FLOT, 73 FLOT). A baseline NLR >_2 was predictive for worse DFS (HR 2.78, 95% CI: 1.41-5.50, P<0.01) and OS (HR 2.90, 95% CI: 1.48-5.67, P<0.01). Sustained elevation in NLR was predictive for DFS (HR 1.54, 95% CI: 1.08-2.17, P=0.01) and OS (HR 1.65, 95% CI: 1.17-2.33, P<0.01). An NLR >_2 correlated with worse pCR rates (16% for NLR >_2, 48% for NLR <2, P=0.04). A baseline serum albumin <33 was predictive of worse DFS and OS with a HR of 6.17 (P=0.01) and 4.66 (P=0.01) respectively. Baseline PLR, BMI, and dynamic changes in these markers were not associated with DFS, OS or pCR rates. There was no association of the aforementioned variables with toxicity. Conclusions: This demonstrates that a high inflammatory state represented by an NLR >_2, both at baseline and sustained, is prognostic and predictive of response in patients receiving FLOT or CROSS. Baseline hypoalbuminaemia is predictive of poorer outcomes.
引用
收藏
页码:494 / 503
页数:10
相关论文
共 31 条
[1]  
Al-Batran SE, 2022, J CLIN ONCOL, V40
[2]   Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial [J].
Al-Batran, Salah-Eddin ;
Homann, Nils ;
Pauligk, Claudia ;
Goetze, Thorsten O. ;
Meiler, Johannes ;
Kasper, Stefan ;
Kopp, Hans-Georg ;
Mayer, Frank ;
Haag, Georg Martin ;
Luley, Kim ;
Lindig, Udo ;
Schmiegel, Wolff ;
Pohl, Michael ;
Stoehlmacher, Jan ;
Folprecht, Gunnar ;
Probst, Stephan ;
Prasnikar, Nicole ;
Fischbach, Wolfgang ;
Mahlberg, Rolf ;
Trojan, Joerg ;
Koenigsmann, Michael ;
Martens, Uwe M. ;
Thuss-Patience, Peter ;
Egger, Matthias ;
Block, Andreas ;
Heinemann, Volker ;
Illerhaus, Gerald ;
Moehler, Markus ;
Schenk, Michael ;
Kullmann, Frank ;
Behringer, Dirk M. ;
Heike, Michael ;
Pink, Daniel ;
Teschendorf, Christian ;
Loehr, Carmen ;
Bernhard, Helga ;
Schuch, Gunter ;
Rethwisch, Volker ;
von Weikersthal, Ludwig Fischer ;
Hartmann, Joerg T. ;
Kneba, Michael ;
Daum, Severin ;
Schulmann, Karsten ;
Weniger, Joerg ;
Belle, Sebastian ;
Gaiser, Timo ;
Oduncu, Fuat S. ;
Guentner, Martina ;
Hozaeel, Wael ;
Reichart, Alexander .
LANCET, 2019, 393 (10184) :1948-1957
[3]   Neutrophil-to-Lymphocyte Ratio to Predict the Efficacy of Immune Checkpoint Inhibitor in Upper Gastrointestinal Cancer [J].
Booka, Eisuke ;
Kikuchi, Hirotoshi ;
Haneda, Ryoma ;
Soneda, Wataru ;
Kawata, Sanshiro ;
Murakami, Tomohiro ;
Matsumoto, Tomohiro ;
Hiramatsu, Yoshihiro ;
Takeuchi, Hiroya .
ANTICANCER RESEARCH, 2022, 42 (06) :2977-2987
[4]   Perioperative FLOT superior to ECF/X [J].
Bradley, Conor A. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (08) :465-465
[5]   Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer [J].
Choi, Il Ju ;
Kook, Myeong-Cherl ;
Kim, Young-Il ;
Cho, Soo-Jeong ;
Lee, Jong Yeul ;
Kim, Chan Gyoo ;
Park, Boram ;
Nam, Byung-Ho .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (12) :1085-1095
[6]   An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer [J].
Crumley, A. B. C. ;
McMillan, D. C. ;
McKernan, M. ;
Going, J. J. ;
Shearer, C. J. ;
Stuart, R. C. .
BRITISH JOURNAL OF CANCER, 2006, 94 (11) :1568-1571
[7]   Chemotherapy regimens induce inhibitory immune checkpoint protein expression on stem-like and senescent-like oesophageal adenocarcinoma cells [J].
Davern, Maria ;
Donlon, Noel E. ;
Sheppard, Andrew ;
O' Connell, Fiona ;
Hayes, Conall ;
Bhardwaj, Anshul ;
Foley, Emma ;
O' Toole, Dermot ;
Lynam-Lennon, Niamh ;
Ravi, Narayanasamy ;
Reynolds, John V. ;
Maher, Stephen G. ;
Lysaght, Joanne .
TRANSLATIONAL ONCOLOGY, 2021, 14 (06)
[8]   Clinical prognostic scoring system to aid decision-making in gastro-oesophageal cancer [J].
Deans, D. A. C. ;
Wigmore, S. J. ;
de Beaux, A. C. ;
Paterson-Brown, S. ;
Garden, O. J. ;
Fearon, K. C. H. .
BRITISH JOURNAL OF SURGERY, 2007, 94 (12) :1501-1508
[9]   Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro-oesophageal cancer [J].
den Boer, R. B. ;
Jones, K. I. ;
Ash, S. ;
van Boxel, G. I. ;
Gillies, R. S. ;
O'Donnell, T. ;
Ruurda, J. P. ;
Sgromo, B. ;
Silva, M. A. ;
Maynard, N. D. .
BJS OPEN, 2020, 4 (05) :847-854
[10]   Sarcopenia: Prevalence, and Impact on Operative and Oncologic Outcomes in the Multimodal Management of Locally Advanced Esophageal Cancer [J].
Elliott, Jessie A. ;
Doyle, Suzanne L. ;
Murphy, Conor F. ;
King, Sinead ;
Guinan, Emer M. ;
Beddy, Peter ;
Ravi, Narayanasamy ;
Reynolds, John V. .
ANNALS OF SURGERY, 2017, 266 (05) :822-830